Karyopharm-话题@MedSci

#Karyopharm#

5篇内容 | 720人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1509636, encodeId=e524150963639, content=<a href='/topic/show?id=4ba710418d0' target=_blank style='color:#2F92EE;'>#Karyopharm#</a>, objectTitle=FDA批准Karyopharm的Xpovio（selinexor）用于治疗多发性骨髓瘤, objectType=article, longId=204714, objectId=6286204e1417, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6286204e1417, replyNumber=0, likeNumber=49, createdTime=2020-12-22, rootId=0, userName=mxj1971615, userId=c85310112774, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6286204e1417, moduleTitle=FDA批准Karyopharm的Xpovio（selinexor）用于治疗多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6286204e1417)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509635, encodeId=94a21509635d6, content=<a href='/topic/show?id=4ba710418d0' target=_blank style='color:#2F92EE;'>#Karyopharm#</a>, objectTitle=Karyopharm的口服核出口选择性抑制剂XPOVIO针对多发性骨髓瘤的III期临床试验达到终点, objectType=article, longId=189451, objectId=9d821894518e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9d821894518e, replyNumber=0, likeNumber=23, createdTime=2020-03-07, rootId=0, userName=mxj1971615, userId=c85310112774, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9d821894518e, moduleTitle=Karyopharm的口服核出口选择性抑制剂XPOVIO针对多发性骨髓瘤的III期临床试验达到终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9d821894518e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509634, encodeId=c4b81509634e3, content=<a href='/topic/show?id=4ba710418d0' target=_blank style='color:#2F92EE;'>#Karyopharm#</a>, objectTitle=FDA接受Karyopharm的口服核出口选择性抑制剂XPOVIO的补充新药申请，用于治疗复发或难治的弥漫性大B细胞淋巴瘤, objectType=article, longId=188486, objectId=9acb18848624, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9acb18848624, replyNumber=0, likeNumber=36, createdTime=2020-02-22, rootId=0, userName=mxj1971615, userId=c85310112774, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9acb18848624, moduleTitle=FDA接受Karyopharm的口服核出口选择性抑制剂XPOVIO的补充新药申请，用于治疗复发或难治的弥漫性大B细胞淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9acb18848624)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509633, encodeId=8e771509633d4, content=<a href='/topic/show?id=4ba710418d0' target=_blank style='color:#2F92EE;'>#Karyopharm#</a>, objectTitle=FDA批准Karyopharm的核输出抑制剂Xpovio用于治疗复发或难治的多发性骨髓瘤, objectType=article, longId=174802, objectId=d82e1e480215, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d82e1e480215, replyNumber=0, likeNumber=37, createdTime=2019-07-06, rootId=0, userName=mxj1971615, userId=c85310112774, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d82e1e480215, moduleTitle=FDA批准Karyopharm的核输出抑制剂Xpovio用于治疗复发或难治的多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d82e1e480215)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1509632, encodeId=ea5c1509632bd, content=<a href='/topic/show?id=4ba710418d0' target=_blank style='color:#2F92EE;'>#Karyopharm#</a>, objectTitle=德琪医药与Karyopharm Therapeutics正式启动战略合作，正式进军血液肿瘤领域, objectType=article, longId=139417, objectId=2cad13941ef3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2cad13941ef3, replyNumber=0, likeNumber=29, createdTime=2018-05-31, rootId=0, userName=mxj1971615, userId=c85310112774, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2cad13941ef3, moduleTitle=德琪医药与Karyopharm Therapeutics正式启动战略合作，正式进军血液肿瘤领域, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2cad13941ef3)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Karyopharm

2020-05-29

mxj1971615 (审核中...)

前往app查看评论内容

#Karyopharm#

FDA批准Karyopharm的Xpovio（selinexor）用于治疗多发性骨髓瘤

2020-12-22

mxj1971615 (审核中...)

前往app查看评论内容

#Karyopharm#

Karyopharm的口服核出口选择性抑制剂XPOVIO针对多发性骨髓瘤的III期临床试验达到终点

2020-03-07

mxj1971615 (审核中...)

前往app查看评论内容

#Karyopharm#

FDA接受Karyopharm的口服核出口选择性抑制剂XPOVIO的补充新药申请，用于治疗复发或难治的弥漫性大B细胞淋巴瘤

2020-02-22

mxj1971615 (审核中...)

前往app查看评论内容

#Karyopharm#

FDA批准Karyopharm的核输出抑制剂Xpovio用于治疗复发或难治的多发性骨髓瘤

2019-07-06

mxj1971615 (审核中...)

前往app查看评论内容

#Karyopharm#

德琪医药与Karyopharm Therapeutics正式启动战略合作，正式进军血液肿瘤领域

2018-05-31

科室
- - 订阅+
  - 更多科室
工具
服务